ASCO: Ivonescimab A New Challenger To Keytruda In 1L, PD-L1-High NSCLC?

Akeso/Summit Release New Head-To-Head Results

 
• By Dexter Jie Yan
  
lung cancer
Akeso/Summit contender may challenge Keytruda in PD-L1-high NSCLC • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia